XIIDRA
MARKETED BY: Shire US, IncINDICATION: The FDA has approved Xiidra (lifitegrast ophthalmic solution) 5%, a lymphocyte function–associated antigen- 1 antagonist, for the treatment of the signs and symptoms of dry eye disease. The recommended dosage is 1 drop twice daily in each eye (approximately 12 hours apart).DOSAGE FORM: Ophthalmic solution containing lifitegrast 5% (50 mg/mL)FOR MORE INFORMATION: xiidra.comAKOVAZ
MARKETED BY: Flamel TechnologiesINDICATION: Flamel Technologies has announced the launch of Akovaz, its formulation of ephedrine sulfate for injection, which received FDA approval in April 2016. Ephedrine sulfate is administered parenterally as a pressor agent to address clinically important hypotension in surgical settings.DOSAGE FORM: Injection: 50 mg/mL ephedrine sulfate in a single-use vialFOR MORE INFORMATION: eclatpharma.comZINBRYTA
MARKETED BY: Biogen and AbbVie, IncINDICATION: The FDA has approved Zinbryta (daclizumab), an interleukin- 2 receptor–blocking antibody, for the treatment of adult patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Zinbryta should generally be reserved for patients who have had an inadequate response to 2 or more drugs indicated for the treatment of MS.DOSAGE FORM: Injection: 150 mg/mL solution in a single-dose prefilled syringeFOR MORE INFORMATION: zinbryta.comNAMZARIC
MARKETED BY: AllerganINDICATION: The FDA has approved an expanded label for Namzaric (memantine and donepezil hydrochlorides) extendedrelease, a once-daily fixed-dose combination of an N-methyl-Daspartate receptor agonist and an acetylcholinesterase inhibitor. The new indication allows patients with moderate to severe Alzheimer’s disease who are stabilized on donepezil hydrochloride 10 mg once daily to start combination therapy directly with Namzaric.DOSAGE FORM: Capsules: 7/10, 14/10, 21/10, and 28/10 mgFOR MORE INFORMATION: namzaric.com
